anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Osteoarthritis (OA) is a degenerative bone disease characterized by inflammation as a primary pathology and currently lacks therapeutic interventions to impede its progression. Erigeron breviscapus (Vant.) Hand.-Mazz. (EB) is an east Asian herbal medicine with a long history of use and a wide range of confirmed efficacy against cardiovascular and central nervous system diseases. The purpose of this study is to evaluate whether EB is worthy of further investigation as a treatment for OA based on anti-inflammatory activity. This study aims to assess the potential of EB as a treatment for OA, focusing on its anti-inflammatory properties. Analgesic effects, functional improvements, and inhibition of cartilage destruction induced by EB were evaluated in acetic acid-induced peripheral pain mice and monosodium iodoacetate-induced OA rat models. Additionally, the anti-inflammatory effect of EB was assessed in serum and cartilage tissue in vivo, as well as in lipopolysaccharide-induced RAW 264.7 cells. EB demonstrated a significant alleviation of pain, functional impairment, and cartilage degradation in OA along with a notable inhibition of pro-inflammatory cytokines, including interleukin-1β, interleukin-6, matrix metalloproteinases 13, and nitric oxide synthase 2, both in vitro and in vivo, in a dose-dependent manner compared to the active control. Accordingly, EB merits further exploration as a potential disease-modifying drug for OA, capable of mitigating the multifaceted pathology of osteoarthritis through its anti-inflammatory properties. Nonetheless, additional validation through a broader experimental design is essential to substantiate the findings of this study.
Emotional disorders (ED) are among the most common and most disabling psychological disorders. They involve important costs and a high comorbidity between them. A large number of evidence-based treatment programs (EBT) has shown to be effective; however, there is a difficulty regarding their dissemination, being that it is difficult to train clinicians in the different protocols for different disorders, and a difficulty in the management of patients with comorbidity. The transdiagnostic approach and the incorporation of technologies for the administration of the based-Internet treatments can help to overcome these barriers. In this context, blended treatments, that combine face-to-face therapy with online therapy, are gaining prominence, because they exhibit advantages over traditional intervention and over treatments totally self-administered throughout Internet. Otherwise, the application of treatments in group format also allows to provide EBTs at a lower cost, so that both blended format and group format constitute strategies that allow improve the cost-effectiveness binomial. To our knowledge, no studies that integrate blended with group format for apply a transdiagnostic protocol for ED have been published.

This study will be a two-arm, parallel-group, randomized controlled clinical trial (RCT) in which participants will be randomly assigned to one of two conditions: 1) Face-to-face group transversal protocol (FFGr-TP) and 2) Blended group transversal protocol (BLGr-TP). To carry it out, a total of 144 patients will be needed. Randomization will be stratified by primary diagnosis. Block randomization will be performed within each stratum to ensure that all major diagnoses are equally represented under all conditions. In this trial there will be five evaluation moments: pre-treatment, post-treatment and follow-up at 3, at 6 and at 12 months. During the treatment administration, two messages of support (an email and a SMS) per week will be sent to participants.

The study will be carried out following national and international standards (Declaration of Helsinki and Tokyo, and Declaration of Madrid of the World Psychiatric Association) and has been submitted to the approval of the Research Ethics Committee of the Universitat Jaume I. Participants will be adult people who contact with the Psychological Assistance Service (PAS) of the Universitat Jaume I or who write at email enabled for the study. All participants will be volunteers and they will give their informed consent to participate in the study. The confidentiality and rights of the subjects included in the study will be guaranteed in accordance with the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of the digital rights (LOPDgdd), which adapts Spanish legislation to the General Data Protection Regulation of the European Union (RGPD).
Concomitant administration of REGONOL ® (pyridostigmine bromide injection, USP) and 4-aminopyridine has been reported to delay the onset of action of REGONOL ®. 9

### Antibiotics

Parenteral administration of high doses of certain antibiotics may intensify or produce neuromuscular block through their own pharmacologic actions. The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. If these or other newly introduced antibiotics are used in conjunction with nondepolarizing neuromuscular blocking drugs during surgery, unexpected prolongation of neuromuscular block or resistance to its reversal should be considered a possibility.

### Other

Experience concerning injection of quinidine during recovery from use of nondepolarizing muscle relaxants suggest that recurrent paralysis may occur. This possibility must be considered when administering anticholinesterase agents to antagonize neuromuscular blockade induced by nondepolarizing muscle relaxants.

Electrolyte imbalance and diseases which lead to electrolyte imbalance, such as adrenal cortical insufficiency, have been shown to alter neuromuscular blockade. Depending on the nature of the imbalance, either enhancement or inhibition may be expected. Magnesium salts, administered for the management of toxemia of pregnancy, may enhance the neuromuscular blockade. The possibility that such circumstances may interfere with the restoration of neuromuscular function should be considered when administering REGONOL ®.
Text messaging frame = safety and cleanness of clinic site. Text parents of children 0-2 years old who are due and due soon for a vaccine across the entire NYU-Brooklyn Family Health Center network.
FIELD: medicine. SUBSTANCE: method involves evaluating renal and prerenal properties of kidney injuries, central and peripheral hemodynamics indices and infectious toxicosis degree in pre- and postoperative period. Kidney function and central and peripheral hemodynamic disorders being observed, II-III order infectious toxicosis being detected, crystalloid preparation are applied. 0.5% dopamine solution at a dose of 3-20 mcg/kg of body mass per min and newly frozen plasma at a dose of 15- 30 ml/kg per day. The value of the mentioned indices being in norm, polycrystalloid preparations only are introduced. Pre-operative period is prolonged as long as possible to reach the most full restoration of kidney functions. EFFECT: enhanced effectiveness of treatment; low risk of postoperative complications. 1 dwg, 5 tbl
Given the toxicity of high dose cisplatin, attention has focused on identifying patients at lower risk for failure who may potentially benefit from less aggressive chemoradiotherapy approaches. HPV-positive Head and Neck Cancer responds favorably to radiation therapy. This has prompted investigators to suggest that patients with these cancers might be "over-treated" and unnecessarily subjected to the toxicity of intensive chemoradiotherapy with excessively high radiation doses.

This study will select patients with HPV-positive Head and Neck cancer for attenuated therapy and may have important implications for individualization of care in the future. The regimen of carboplatin and paclitaxel was selected for the induction chemotherapy phase because of its ease of administration, improved toxicity profile, high rates of dose delivery, and excellent published results showing high response rates and overall survival. This study will use induction chemotherapy primarily as a means to select HPV-positive Head and Neck Cancer patients, who may benefit from significant radiation dose de-intensification in the concurrent chemoradiotherapy phase of treatment. The rationale for this risk-adapted approach to local therapy based on HPV status is to administer effective comprehensive treatment individualized at diagnosis and after assessment of response to induction chemotherapy (for patients with HPV-positive tumors), thus avoiding unnecessary and potentially toxic treatment, and hence optimizing the therapeutic ratio.
Unfortunately, I suffered from prolapse of lumbar intervertebral disc which cannot be cured by taking medicaments and cause no death in the medical field at present, but causes unbearable pains for me. After careful reflection, I decided to use the medicament which cured the bony spur for my wife six years ago. The medicament was tied up at the lumbar intervertebral disc protrusion part and magically I could leave a sickbed to work in three days, and thirty days later, CT diagnosis showed that the protruded intervertebral disc was recovered and the prolapse of lumbar intervertebral disc was cured. I call the medicament as the medicament special for bony spur and apophysis (prolapse of lumbar intervertebral disc). The medicament special for the bony spur and the apophysis (prolapse of lumbar intervertebral disc) belongs to the management by drug management institutions and is a most welcome good medicament for patients, and is tied up at affected parts according to the method of the description only after an orthipedist in a hospital confirms that a patient suffers from the bony spur and the prolapse of lumbar intervertebral disc through CT images. 30 days later, because the potency of the medicament is infiltrated (absorbed by) into skins and muscles to recover and cure the formed the bony spur and the protruded intervertebral disc, the miraculous new medicament ends the history that no medicament can cure the bony spur and the prolapse of lumbar intervertebral disc in the medical field at present. I deliberate that the medicament can surely cure cervical intervertebral disc herniation and lumbar sprain, and may also has excellent curative effect of treating periarthritis humeroscapularis, arthritis, sciatica and similar diseases.
PURPOSE: Risk stratification of regional recurrence (RR) is clinically important in the design of adjuvant treatment and surveillance strategies in patients with clinical stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). This study aimed to develop a radiomics model predicting occult lymph node metastasis (OLNM) using surgical data and apply it to the prediction of RR in SBRT-treated early-stage NSCLC patients.
METHODS AND MATERIALS: Patients with clinical stage I NSCLC who underwent curative surgery with systematic lymph node dissection from January 2013 to December 2018 (the training cohort) and from January 2019 to December 2020 (the validation cohort) were included. A preoperative computed tomography-based radiomics model, a clinical feature model, and a fusion model predicting OLNM were constructed. The performance of the 3 models was quantified and compared in the training and validation cohorts. Subsequently, the radiomics model was used to predict RR in a cohort of consecutive SBRT-treated early-stage NSCLC patients from 2 academic medical centers.
RESULTS: A total of 769 patients were included. Eight computed tomography features were identified in the radiomics model, achieving areas under the curves of 0.85 (95% CI, 0.81-0.89) and 0.83 (95% CI, 0.80-0.88) in the training and validation cohorts, respectively. Nevertheless, adding clinical features did not improve the performance of the radiomics model. With a median follow-up of 40.0 (95% CI, 35.2-44.8) months, 32 of the 213 patients in the SBRT cohort developed RR and those in the high-risk group based on the radiomics model had a higher cumulative incidence of RR (P < .001) and shorter regional recurrence-free survival (P = .02), progression-free survival (P = .004) and overall survival (P = .006) than those in the low-risk group.
CONCLUSIONS: The radiomics model based on pathologically confirmed data effectively identified patients with OLNM, which may be useful in the risk stratification among SBRT-treated patients with clinical stage I NSCLC.
The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females. Together, the results suggest SAS1R is a proteolytically active, oocyte and early embryo specific oolemmal metalloprotease receptor for the sperm intra-acrosomal ligand SLLP1 and is a target for regulating fertilization and as a contraceptive.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic dosage form having excellent usability and utilizing optical characteristics of pearly powder.  <P>SOLUTION: The cosmetic is obtained by including (1) the pearly powder and (2) a polyhydric alcohol. Powder having properties assuming a pearly luster by an interference color on the surface by a surface structure can be exemplified as the pearly powder. Furthermore, powder obtained by vapor depositing a thin film of a metal oxide such as titanium dioxide on the surface of thin platy powder so as to assume the interference color with a lattice structure created by a metal oxide of the thin film and powder prepared by laminating resin flakes such as an epoxy resin flakes so as to assume the interference color by joining the layers can be exemplified. A capsule including the polyhydric alcohol is preferred as the form of the contained polyhydric alcohol.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The participants allocated to the control group will also be asked to attend a single night in-laboratory PSG. The NIV settings will not be adjusted throughout the PSG ("sham" PSG). Participants in the control group will retain their original settings after the sham PSG, and will be asked to continue to use NIV in this manner for the subsequent 7 week intervention period.
Participants with UGT1A1\*1/\*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
The present invention relates to methods of treating intrauterine adhesions using stem cells. The method relates to a cell preparation, which comprises amniotic mesenchymal stem cells and a medicinal solvent. The medicinal solvent is water; the cell preparation is a preparation for injection. The amnion mesenchymal stem cells are subcultured to 1-20 generations, and the concentration of the amnion mesenchymal stem cells is (1-8) multiplied by 10 6 The plant growth regulator is characterized by also comprising sodium chloride, for example, the concentration of the sodium chloride is 7-10 mg/ml. The cell preparationIs prepared by the following steps: dissolving pharmaceutical adjuvants such as sodium chloride with appropriate amount of water to obtain saline solution; and transferring the mesenchymal stem cells obtained by subculture to a centrifuge tube for centrifugation, discarding supernatant, and adding saline solution to resuspend the cells to obtain the cell preparation. The invention also relates to the use of said cell preparation for the preparation of a medicament for the treatment of intrauterine adhesions. The method, the cell preparation and the pharmaceutical use of the invention use the cell preparation of the amniotic mesenchymal stem cells to treat the intrauterine adhesion and promote the repair of endometrium, and show excellent technical effects as described in the specification.
Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
AIM: To describe the epidemiological and clinical data of impaired functional outcome secondary to anterior resection of the rectum and to identify the predictive factors of major low anterior resection syndrome (LARS) Methods: This retrospective study considered patients operated on for rectal tumors in surgical department in our hospital, between January 1st,2009 and December 31st, 2021. The primary outcome measure was the development of a major LARS immediately or after stoma closure. In order to identify independent predictors of major LARS, patients were divided into two groups: the "Major LARS" group and the "No Major LARS" group, and then we carried out a descriptive study, followed by an analytical study with logistic regression.
RESULTS: We enrolled 42 patients operated for rectal tumor and had an anterior resection. Half of our patients developed LARS of which 14 developed major LARS. The median time to onset of LARS symptoms was 9 [2 -24] months. At the end of this study, 2 factors were retained: age (OR=2.48; CI95% [1.2- 5.10], p=0.012) and pT3T4 stage (OR=5.95; CI95% [1.07- 33.33], p=0.041) as independent predictive factors of a major LARS. Neoadjuvant therapy was also a risk factor for major LARS in our study with a statistically significant difference (p=0.025) between the two groups "Major LARS" and "No major LARS".
CONCLUSION: LARS should be appropriately considered in the management of rectal cancer. Based on our results and data from the literature, age and mesorectal invasion were found to be independent predictors of major LARS.
BACKGROUND: Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan.
METHODS: From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied.
RESULTS: The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens' first-month costs were 612 851-849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000-800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN.
CONCLUSION: First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.
The invention discloses a traditional Chinese medicine and especially discloses a traditional Chinese medicine for treating hand and foot rhagadia. The traditional Chinese medicine for treating hand and foot rhagadia comprises: by weight, 60 parts of pig skin, 20 parts of lily, 15 parts of milkvetch root, 20 parts of Chinese yam, 12 parts of fleeceflower root, 10 parts of arnebia root, and 15 parts of garden burnet root. The traditional Chinese medicine for treating hand and foot rhagadia is taken after water decoction. Each dose of the traditional Chinese medicine is subjected to water decoction twice and is taken in 5 times. In one treatment course, five doses of the traditional Chinese medicines are taken and after 2-3 treatment courses, hand and foot rhagadia can be cured. The traditional Chinese medicine can thoroughly cure hand and foot rhagadia, has obvious effects, and adopts the raw materials having low costs and no side-effect.
A stable smallpox vaccine is prepared by blending vaccinia virus infected tissue with a substantially neutral aqueous suspension medium, treating the resulting blend to effect mechanical separation of relatively large particle of cells and debris while leaving the vaccinia virus in suspension, adding an antibiotic or mixture of antibiotics to the thus clarified virus suspension and allowing antibiotic activity to proceed for at least one day, treating the antibiotic treated virus suspension to effect a mechanical separation of vaccinia virus from the antibiotic solution, resuspending the thus separated vaccinia virus in a substantially neutral aqueous suspension medium and freezing said virus suspension.  The infected tissue is preferably calf pulp.  Phenol to a concentration of not more than 0.5% w./v. is added to the virus suspension, preferably at a stage prior to separation of the virus from the antibiotic-containing solution. The frozen vaccine may be vacuum dried or it may be thawed.  The antibiotic may be penicillin, streptomycin, chlortetracycline, oxytetracycline, bacitracin, tyrothricin, chloromycetin, or a mixture of polymyxin B sulphate, neomycin sulphate and dihydrostreptomycin, which is preferred.  The separated vaccinia virus may be resuspended in a neutral aqueous suspension medium containing a water-soluble or water-dispersible therapeutically acceptable and injectable extender, e.g. peptone, polyvinylpyrrolidone, dextran, albumen, vegetable gums, animal sera and sugars such as sucrose and lactose.  The preferred suspension medium is an aqueous phosphate citric acid buffer of pH about 7.2.
Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.